Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff Settleman

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Cell|March 12, 2003
DOCK4, a GTPase activator, is disrupted during tumorigenesisVijay Yajnik, Charles Paulding, Raffaella Sordella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway ActivationVictoria E Wang, Jenny Y Xue, Dennie T Frederick, et al.
Cancer Discovery|December 12, 2012
Noncovalent wild-type-sparing inhibitors of EGFR T790MHo-June Lee, Gabriele Schaefer, Timothy P Heffron, et al.
Cell|April 8, 2010
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulationsSreenath V Sharma, Diana Y Lee, Bihua Li, et al.
Nature|July 6, 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsTimothy R Wilson, Jane Fridlyand, Yibing Yan, et al.
The New England Journal of Medicine|May 1, 2004
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibThomas J Lynch, Daphne W Bell, Raffaella Sordella, et al.
Nature Medicine|January 25, 2012
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancerClara Montagut, Alba Dalmases, Beatriz Bellosillo, et al.
Nature|July 14, 2015
Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolismRushika M Perera, Svetlana Stoykova, Brandon N Nicolay, et al.
International Journal of Oncology|August 28, 2012
Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutationsFabrizio Galimberti, Alexander M Busch, Fadzai Chinyengetere, et al.
Plos One|March 8, 2013
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neckDavid S Shames, Juliet Carbon, Kim Walter, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Cell|March 12, 2003
DOCK4, a GTPase activator, is disrupted during tumorigenesisVijay Yajnik, Charles Paulding, Raffaella Sordella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway ActivationVictoria E Wang, Jenny Y Xue, Dennie T Frederick, et al.
Cancer Discovery|December 12, 2012
Noncovalent wild-type-sparing inhibitors of EGFR T790MHo-June Lee, Gabriele Schaefer, Timothy P Heffron, et al.
Cell|April 8, 2010
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulationsSreenath V Sharma, Diana Y Lee, Bihua Li, et al.
Nature|July 6, 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsTimothy R Wilson, Jane Fridlyand, Yibing Yan, et al.
The New England Journal of Medicine|May 1, 2004
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibThomas J Lynch, Daphne W Bell, Raffaella Sordella, et al.
Nature Medicine|January 25, 2012
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancerClara Montagut, Alba Dalmases, Beatriz Bellosillo, et al.
Nature|July 14, 2015
Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolismRushika M Perera, Svetlana Stoykova, Brandon N Nicolay, et al.
International Journal of Oncology|August 28, 2012
Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutationsFabrizio Galimberti, Alexander M Busch, Fadzai Chinyengetere, et al.
Plos One|March 8, 2013
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neckDavid S Shames, Juliet Carbon, Kim Walter, et al.
Pageof 7